Comparison of Dual Antiplatelet Therapy De-escalation by Dose Reduction Versus Switching in Patients Undergoing PCI
Phase 4
78
about 1.8 years
18+
1 site in FL
About this study
This trial is testing whether de-escalating dual antiplatelet therapy (DAPT) by reducing the dose of prasugrel or switching from a more potent P2Y12 inhibitor to clopidogrel provides similar benefits for preventing blood clots after heart procedures. The goal is to compare these two methods of DAPT de-escalation and determine if they are equally effective at preventing bleeding while still protecting against clots.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Prasugrel 5 mg
- 2.Take clopidogrel 75 mg
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
prasugrel, clopidogrel (Antiplatelet; blocks ADP receptors on platelets to prevent aggregation)
oral (Oral Tablet), oral
Cardiology / Heart